Cardiol Therapeutics (CRDL) investor relations material

Company overview and business model

• Late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease, focusing on pericarditis, myocarditis, and heart failure.

• Lead candidate CardiolRx™ targets inflammasome pathway activation; programs include MAVERIC (recurrent pericarditis) and ARCHER (acute myocarditis).

• Developing CRD-38, a novel subcutaneous drug for inflammatory heart disease, with IND-enabling studies underway.

Financial performance and metrics

• General and administrative expenses for the six months ended June 30, 2026, were $9.5M, slightly down from $9.6M in the prior year period.

• For the year ended December 31, 2025, general and administrative expenses decreased to $20.3M from $26.3M in 2024, mainly due to lower share-based compensation and reduced investor outreach.

• Cash and cash equivalents as of June 30, 2026, were $10.1M; total capitalization was $24.0M.

Use of proceeds and capital allocation

• Net proceeds from offerings will fund business objectives, general corporate purposes, working capital, debt repayment, and potential acquisitions.

• Prior offering proceeds were primarily allocated to CardiolRx™ clinical development and general expenses; remaining funds may be reallocated based on strategy and market conditions.

• Estimated costs for key milestones: $5M for Phase III MAVERIC completion, $4M for CRD-38 IND-enabling work, $3M for Phase I CRD-38 study.